Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelets as a source of vasoactive mediators.

K Schrör1, M Braun

  • 1Institut für Pharmacokologie, Heinrich-Heine-Universität Düsseldorf, FRG.

Stroke
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Importance of acetylsalicylic acid in primary prevention : ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.]

Der Internist·2019
Same author

[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].

Der Internist·2017
Same author

Why we should not skip aspirin in cardiovascular prevention.

Hamostaseologie·2015
Same author

Inhibition of antiplatelet effects of aspirin by nonopioid analgesics.

Clinical pharmacology and therapeutics·2015
Same author

[Aspirin and venous thromboses].

Der Internist·2015
Same author

[Perioperative aspirin treatment in patients undergoing surgery: Perioperative Ischemic Evaluation 2 (POISE-2)].

Der Internist·2014

Platelets release vasoconstrictors like thromboxane A2 that constrict cerebral arteries. Endothelial dysfunction in stroke exacerbates this, highlighting the importance of anti-platelet therapies.

Area of Science:

  • Vascular biology
  • Platelet physiology
  • Neuroscience

Background:

  • Human platelets secrete vasoactive mediators, including arachidonic acid metabolites and biogenic amines.
  • Compounds like thromboxane A2, PGF2 alpha, and serotonin (5-HT) potently constrict human cerebral arteries.
  • The vascular endothelium normally counteracts these platelet-derived vasoconstrictors and prothrombotic effects.

Purpose of the Study:

  • To investigate the role of platelet-derived vasoconstrictors in cerebral artery function.
  • To understand the impact of endothelial dysfunction on platelet mediator activity in conditions like stroke.
  • To evaluate the significance of inhibiting platelet hyperfunction for preventing cerebral thromboembolism.

Main Methods:

  • In vitro studies on human cerebral arteries.

Related Experiment Videos

  • Analysis of mediator release from stimulated platelets.
  • Assessment of endothelial function and its interaction with platelets.
  • Evaluation of the effects of anti-platelet drugs like acetylsalicylic acid and ticlopidine.

    • Main Results:

    • Platelet mediators (thromboxane A2, PGF2 alpha, 5-HT) are potent cerebral artery constrictors.
    • Endothelial dysfunction, common in cerebral ischemia and stroke, is linked to increased platelet reactivity and mediator release.
    • Inhibition of platelet function with acetylsalicylic acid or ticlopidine shows protective effects in high-risk patients.

    Conclusions:

    • Platelet-derived vasoconstrictors play a significant role in cerebral vasoconstriction and thromboembolism.
    • Endothelial dysfunction exacerbates the pro-vasoconstrictive and pro-thrombotic actions of platelets.
    • Anti-platelet therapies are crucial for managing conditions associated with platelet hyperreactivity and cerebral vascular events.
    • Further research is needed to determine the efficacy of selective thromboxane inhibitors.